BCL2 blockade overcomes MCL1 resistance in multiple myeloma

Leukemia. 2019 Aug;33(8):2098-2102. doi: 10.1038/s41375-019-0421-0. Epub 2019 Feb 28.

Affiliations

¹ Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, 02114, USA.
² Broad Institute, Cambridge, MA, 02142, USA.
³ Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Boston, MA, USA.
⁴ Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, 02114, USA. NRAJE@mgh.harvard.edu.

PMID: 30816329
DOI: 10.1038/s41375-019-0421-0

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / therapeutic use*
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
Cellular Microenvironment
Drug Resistance, Neoplasm
Humans
Macrocyclic Compounds / therapeutic use*
Multiple Myeloma / drug therapy*
Myeloid Cell Leukemia Sequence 1 Protein / antagonists & inhibitors*
Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors*
Sulfonamides / therapeutic use*

Substances

AZD5991
Antineoplastic Agents
Bridged Bicyclo Compounds, Heterocyclic
MCL1 protein, human
Macrocyclic Compounds
Myeloid Cell Leukemia Sequence 1 Protein
Proto-Oncogene Proteins c-bcl-2
Sulfonamides
venetoclax